Francisella tularensis is a gram-negative coccobacillus that causes tularemia, a highly infectious zoonotic disease. Because of its high infectivity, ease of dissemination, and ability to cause severe disease and death, F. tularensis is designated by the Centers for Disease Control and Prevention as a category A select bacterial agent [1]. Differentiation of the 4 closely related subspecies of F. tularensis (tularensis, holarctica, mediaasiatica, and novicida) depends on epidemiology, infection source, and clinical manifestations [2]. F. tularensis subsp tularensis (type A) is highly virulent to all mammalian species, including humans, with mortality rates of 30%–60% in systemic infection following inhalation. F. tularensis subsp holarctica (type B) is less virulent to humans but can cause chronic debilitating illness. Both type A and type B are highly virulent in mice. The F. tularensis live attenuated vaccine strain (Ft.LVS), which was derived by serial in vitro passage of a type B strain [3], has been used to immunize high-risk groups, but currently is not licensed as a vaccine because of an incomplete understanding of its attenuated virulence (at a genetic level), protective properties, and untoward reactions. Multiple strategies have been employed to develop a protective vaccine against tularemia, including the use of killed whole bacteria [4], subunits [5–9] and live attenuated strains [10–12]. However, inadequate knowledge of the protective antigens and virulence mechanisms of F. tularensis [13–15] still renders it difficult to develop a fully satisfactory vaccine. The lipopolysaccharide (LPS) of F. tularensis has attracted considerable interest because of its unusual biological and structural properties and its key role in virulence. Unlike the LPSs of other gram-negative bacteria, that of F. tularensis does not induce innate immune responses [16, 17]. However, the O-polysaccharide (O-PS) portion of the LPS, when used in a glycoconjugate vaccine, reportedly plays a major role in immunity [18, 19] by inducing specific protective antibodies [20]. Cooperation of the humoral and cellular arms of the immune system is essential for effective protection against tularemia [21, 22]. We recently used the avirulent, O-PS-negative strain (Ft.LVS::δwbtA) deleted in wbtA (accession no. {"type":"entrez-nucleotide","attrs":{"text":"DQ353940","term_id":"90654210","term_text":"DQ353940"}}DQ353940) together with a glycoconjugate (tetanus toxoid–O-PS) as a combinatorial vaccine [20] in which the glycoconjugate-induced humoral immunity and the wbtA mutant accounted for cellular immunity. This combination of immunogens conveyed enhanced protection against both type A (SchuS4) and type B (FSC108) strains (intradermal infection) as well as partial protection (enhanced over that provided by either component alone) against intranasal infection with type A strains. The wzy gene (FTL_0598) of F. tularensis is located on the genome at the O-antigen locus. This gene encodes an O-antigen polymerase (Wzy) that is genetically and structurally related to the wzy genes responsible for the polymerization of heteropolymeric O antigens in gram-negative bacteria [23, 24]. We have functionally characterized a wzy deletion mutant (Ft.LVS::Δwzy) and have shown that Wzy is responsible for polymerization of the O-PS during LPS synthesis [24]. An important point is that the mutant expresses only 1 repeating unit of O antigen on its cell surface [24], whereas the parental Ft.LVS expresses multiple repeating units. Herein we show, in a mouse model of infection, that the Ft.LVS::Δwzy is a good candidate vaccine against tularemia. Ft.LVS::Δwzy is attenuated by at least 7 log10 compared with the parental Ft.LVS. Moreover, compared with the Ft.LVS::ΔwbtA, the Ft.LVS::Δwzy is significantly more protective against type A strains. While the Ft.LVS::ΔwbtA induced only cellular immunity [19, 20], the Ft.LVS::Δwzy mutant induced both cellular and humoral immunity, as its nonrepeating single unit of O antigen induced protective antibodies reacting with full-length O-PS. The Ft.LVS::Δwzy mutant offers some significant advantages over the combinatorial vaccine (ie, the O-PS glycoconjugate plus the Ft.LVS::ΔwbtA), as it is significantly more protective against type A strains, and is much easier to administer.